Drugs / Cangrelor
Cangrelor
also known as
AR-C69931XX · Kangrexal · Kengreal · Kengreal (USA) · KENGREXAL (cangrelor) · Kengrexal (EU)
Small molecule targets P2RY12 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | KENGREAL | — | 2015-06-22 | fda.gov ↗ |
| Approved | EU (EMA) | Kengrexal | — | 2015-03-23 | europa.eu ↗ |
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02765633 | Jan 2017 → Aug 2019 | congenital cardiovascular shunt | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT00699504 | Jun → Nov 2008 | — | The Medicines Company | Completed | No outcome recorded |
| Phase 1 | NCT00102674 | Mar → May 2005 | — | The Medicines Company | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06792643 | Apr 2024 → Oct 2025 overdue | cardiogenic shock, platelet disorder, undefined | IRCCS San Raffaele | Recruiting | No outcome recorded |
| Phase 2 | NCT03862651 | Jun 2019 → Dec 2020 | platelet aggregation, spontaneous | Ospedale Santa Croce-Carle Cuneo | Unknown | No outcome recorded |
| Phase 2 | NCT03102723 | Oct 2017 → Dec 2022 | ST-elevation myocardial infarction | National Heart Centre Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT01979445 | Dec 2013 → Jan 2014 | coronary artery disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 2 | NCT01852019 | Jun → Jul 2013 | coronary artery disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 2 | NCT01766466 | Jan → Feb 2013 | coronary artery disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 2 | NCT00767507 | Oct 2008 → Jun 2011 | acute coronary syndrome | The Medicines Company | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04667078 | Mar 2022 → Mar 2030 expected | ischemic disease | Fondation Ophtalmologique Adolphe de Rothschild | Recruiting | No outcome recorded |
| Phase 3 | NCT01156571 | Sep 2010 → Dec 2012 | acute coronary syndrome, atherosclerosis | The Medicines Company | Completed | No outcome recorded |
| Phase 3 | NCT00385138 | Sep 2006 → May 2009 | acute coronary syndrome, atherosclerosis | The Medicines Company | Terminated | No outcome recorded |
| Phase 3 | NCT00305162 | Apr 2006 → May 2009 | acute coronary syndrome, myocardial infarction | The Medicines Company | Terminated | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07225842 | Feb 2026 → Sep 2027 expected | coronary artery disorder | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06089577 | Nov 2023 → Oct 2025 overdue | coronary artery disorder | Federico II University | Recruiting | No outcome recorded |
| Phase 4 | NCT04927949 | Jun 2021 → Mar 2023 | ST-elevation myocardial infarction | University Hospital, Caen | Completed | No outcome recorded |
| Phase 4 | NCT04668144 | Feb 2021 → Feb 2023 | acute coronary syndrome, coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT04634162 | Feb → Aug 2021 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT04005729 | Jul 2019 → Nov 2021 | acute coronary syndrome, cardiac arrest | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT03551964 | Aug 2018 → Feb 2024 | acute myocardial infarction, cardiogenic shock | Faculty Hospital Kralovske Vinohrady | Completed | No outcome recorded |
| Phase 4 | NCT03247738 | Nov 2017 → Dec 2018 | ST-elevation myocardial infarction | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT02943369 | Jul → Nov 2017 | ST-elevation myocardial infarction | Attikon Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02978040 | Jul 2017 → Aug 2019 | ST-elevation myocardial infarction, coronary artery disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT03043274 | Jan 2017 → May 2019 | ST-elevation myocardial infarction | Khaled Ziada, MD | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01103440 Comparator | Apr 2007 → Jun 2009 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03182855 Comparator | Sep 2018 → Jun 2019 | ST-elevation myocardial infarction, acute coronary syndrome | University of Aarhus | Unknown | No outcome recorded |
| Phase 4 | NCT03273075 Comparator | Sep 2017 → May 2021 | acute coronary syndrome, cardiac arrest | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT02733341 Comparator | Jul 2016 → Oct 2018 | ST-elevation myocardial infarction, acute coronary syndrome, vascular occlusion disorder | The Royal Wolverhampton Hospitals NHS Trust | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cangrelor | “Cangrelor” NCT01103440 ↗28 |
| Known as | AR-C69931XX | ChEMBL registry synonym — accepted as the source's own label CHEMBL334966 ↗ |
| Known as | Kangrexal | “Cangrelor (Kangrexal) with an i.v. loading bolus (30mg/Kg) followed by i.v. infusion (4mg/Kg/min) for 2 hours.” NCT06089577 ↗ |
| Known as | Kengreal | ChEMBL registry synonym — accepted as the source's own label CHEMBL334966 ↗ |
| Known as | Kengreal (USA) | “Cangrelor [Kengrexal (EU), Kengreal (USA)] has been licensed for use in Europe, USA and the UK since March 2015, June 2015 and July 2015 respectively.” NCT02733341 ↗ |
| Known as | KENGREXAL (cangrelor) | “KENGREXAL® (cangrelor)” NCT03862651 ↗ |
| Known as | Kengrexal (EU) | “Cangrelor [Kengrexal (EU), Kengreal (USA)] has been licensed for use in Europe, USA and the UK since March 2015, June 2015 and July 2015 respectively.” NCT02733341 ↗ |
| Action | Inhibit | “is an intravenous blocker of the adenosine diphosphate receptor P2Y(12)” PMID 19915221 ↗ Dec 20091“Purinergic receptor P2Y12 antagonist” CHEMBL334966 ↗ |
| Modality | Small molecule | “The recently authorized parenteral cangrelor is an adenosine triphosphate (ATP) analogue” NCT03273075 ↗ |
| Route | Intravenous | “is an intravenous blocker” PMID 19915221 ↗ Dec 2009 |
| Target | P2RY12 | “Purinergic receptor P2Y12 antagonist” CHEMBL334966 ↗ |